- Home
- KMPR vs SYRE Comparison
KMPR vs SYRE Comparison
Compare KMPR & SYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | KMPR | SYRE |
|---|---|---|
| Founded | 1990 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.6B |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | KMPR | SYRE |
|---|---|---|
| Price | $31.70 | $40.14 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 7 |
| Target Price | $47.50 | ★ $55.57 |
| AVG Volume (30 Days) | ★ 890.6K | 709.5K |
| Earning Date | 01-01-0001 | 05-19-2026 |
| Dividend Yield | ★ 3.93% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.07 | N/A |
| P/E Ratio | $14.38 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $30.05 | $10.91 |
| 52 Week High | $69.83 | $45.76 |
Technical Indicators
Market Signals| Indicator | KMPR | SYRE |
|---|---|---|
| Relative Strength Index (RSI) | 35.50 | 56.66 |
| Support Level | $30.35 | $14.62 |
| Resistance Level | $41.66 | $45.76 |
| Average True Range (ATR) | 1.02 | 2.35 |
| MACD | 0.24 | -0.24 |
| Stochastic Oscillator | 43.54 | 47.96 |
Price Performance
Historical ComparisonAbout KMPR Kemper Corporation
Kemper Corp is a diversified insurance company that provides services in property and casualty insurance, along with life and health insurance. The company's property and casualty segment offers personal and commercial lines for home and automotive products. The company conducts its operations through two operating segments: Specialty Property & Casualty Insurance, and Life Insurance.
About SYRE Spyre Therapeutics Inc.
Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.